:max_bytes(150000):strip_icc()/Trulicityvs.OzempicWhatstheDifference-bbf35a57b7794709be23d90fd4e44a75.jpg)
Quick Dispatch:
Your surpass cvot tirzepatide Tirzepatide Demonstrates Cardioprotective Effects in SURPASS-CVOT Trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surpass cvot tirzepatide Tirzepatide Demonstrates Cardioprotective Effects in SURPASS-CVOT Trial ships.
Need Help?
Questions about surpass cvot tirzepatide Tirzepatide Demonstrates Cardioprotective Effects in SURPASS-CVOT Trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surpass cvot tirzepatide Tirzepatide Demonstrates Cardioprotective Effects in SURPASS-CVOT Trial in your area.
SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized
20.46
In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx
27.49
Original Article: Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes (SURPASS-CVOT)
29.93
SURPASS-CVOT: Tirzepatide Significantly Reduces Major Kidney Events Compared to Dulaglutide in T2D
26.06
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
21.45
Overview of key tirzepatide clinical trials and their cardiovascular
28.58
Post hoc analysis of SURPASS-CVOT trial: Tirzepatide was associated with a lower risk of the 6-component cardiorenal endpoint, driven by reduction in all-cause mortality, compared to dulaglutide in patients with T2D and
23.94
